Alberta Investment Management Corp Boosts Stake in DexCom, Inc. (NASDAQ:DXCM)

Alberta Investment Management Corp boosted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 13.7% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 302,357 shares of the medical device company's stock after acquiring an additional 36,500 shares during the period. Alberta Investment Management Corp owned 0.08% of DexCom worth $23,514,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Creative Planning increased its position in shares of DexCom by 22.3% during the third quarter. Creative Planning now owns 59,573 shares of the medical device company's stock worth $3,994,000 after acquiring an additional 10,880 shares in the last quarter. Blue Trust Inc. lifted its holdings in shares of DexCom by 101.9% in the third quarter. Blue Trust Inc. now owns 1,779 shares of the medical device company's stock valued at $119,000 after purchasing an additional 898 shares in the last quarter. Private Advisor Group LLC boosted its position in shares of DexCom by 5.7% during the third quarter. Private Advisor Group LLC now owns 11,318 shares of the medical device company's stock worth $759,000 after buying an additional 608 shares during the period. Aquila Investment Management LLC grew its holdings in shares of DexCom by 50.0% during the third quarter. Aquila Investment Management LLC now owns 42,000 shares of the medical device company's stock worth $2,816,000 after buying an additional 14,000 shares in the last quarter. Finally, Lecap Asset Management Ltd. raised its position in DexCom by 90.8% in the 3rd quarter. Lecap Asset Management Ltd. now owns 47,543 shares of the medical device company's stock valued at $3,187,000 after buying an additional 22,623 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Baird R W upgraded shares of DexCom from a "hold" rating to a "strong-buy" rating in a report on Thursday, January 16th. Citigroup lifted their target price on DexCom from $85.00 to $91.00 and gave the company a "buy" rating in a research report on Wednesday, December 11th. Canaccord Genuity Group upped their target price on DexCom from $99.00 to $103.00 and gave the stock a "buy" rating in a report on Friday, February 14th. Raymond James decreased their price target on DexCom from $115.00 to $99.00 and set a "strong-buy" rating for the company in a research note on Friday, October 25th. Finally, Royal Bank of Canada decreased their target price on shares of DexCom from $120.00 to $115.00 and set an "outperform" rating for the company in a research note on Friday, October 25th. Four investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, DexCom has an average rating of "Moderate Buy" and a consensus target price of $99.06.

DexCom Price Performance

DXCM traded down $0.56 on Friday, hitting $88.78. 3,475,343 shares of the stock were exchanged, compared to its average volume of 3,580,775. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The firm has a market capitalization of $34.69 billion, a price-to-earnings ratio of 62.08, a PEG ratio of 2.31 and a beta of 1.14. The business has a 50-day moving average of $83.26 and a two-hundred day moving average of $75.94.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Sell-side analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Transactions at DexCom

In other news, CEO Kevin R. Sayer sold 33,359 shares of DexCom stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the transaction, the chief executive officer now owns 319,037 shares in the company, valued at approximately $27,727,505.67. The trade was a 9.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jereme M. Sylvain sold 2,090 shares of the firm's stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the transaction, the executive vice president now directly owns 83,526 shares of the company's stock, valued at approximately $7,259,244.66. This represents a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 38,083 shares of company stock worth $3,309,794. Insiders own 0.30% of the company's stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.